Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-Academy-Meeting-2022-1000x250

Educational Grant

Bristol Myers Squibb 

SL-Bristol-Myers-Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We work every day to transform patients’ lives through science. We are proud of the advancements we have made in oncology, hematology, immunology and cardiovascular disease.

Supporters

Servier 

SL-Servier

Cancer is the second leading cause of death in the world. This is why Servier has made oncology one of its foremost priorities, focusing on hard-to-treat cancers for small targeted populations, such as digestive, hematological and pediatric cancers. To date Servier ‘s oncology pipeline is made of 23 projects in clinical development, balanced between monoclonal antibodies and targeted small molecules.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.